Non-coding RNAs in gene therapy: mechanisms, delivery strategies, and clinical translation
Open Access
- 17 February 2026
- journal article
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-25
Abstract
Non-coding RNAs (ncRNAs) have evolved from being regarded as “genomic noise” to a significant asset for gene therapy, enabling programmable control of transcription, RNA stability, and translation. This review integrates ncRNA biogenesis, therapeutic mechanisms, delivery engineering, and clinical translation across RNA subclasses (miRNAs, siRNAs, piRNAs, lncRNAs, and circRNAs), connecting molecular discoveries to design parameters and regulatory-grade development standards. Non-coding RNAs operate through sequence-specific silencing, decoy or sponging interactions, scaffolding of protein complexes, and epigenetic alteration across several modalities, creating multiple therapeutic opportunities while necessitating specialized requirements for cellular localization and target validation. Comparative synthesis indicates that siRNA therapeutics have progressed most swiftly due to dependable cytosolic target engagement and modular chemistry, with approved treatments such as patisiran demonstrating prolonged in vivo gene silencing. Conversely, early miRNA replacement endeavors (e.g., MRX34) demonstrate how innate immune activation, formulation-specific toxicity, and clinical variability might compromise favorable biological results. Nuclear accessibility, tissue-specific expression, and inadequate mechanistic characterization represent substantial translational barriers for lncRNA and circRNA treatments. Delivery emerges as the principal rate-limiting factor, as lipid nanoparticles, viral vectors, polymers, and extracellular vesicles each negotiate tissue tropism, endosomal escape, manufacturability, and immunogenicity. These insights collectively support a translational roadmap that prioritizes safer and more selective delivery methods, including ligand-guided and hybrid carriers; clearly defined endpoints that distinguish preclinical potential from clinical validation; and sophisticated design strategies incorporating RNA editing technologies and AI-driven optimization.Keywords
Funding Information
- National Institutes of Health (5U2GPS000930-02)
This publication has 160 references indexed in Scilit:
- Circular RNAs in human diseasesMedcomm, 2024
- Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapyMedcomm, 2023
- RNA therapeutics in the clinicBioengineering & Translational Medicine, 2022
- Challenges of microRNA‐based biomarkers in clinical application for cardiovascular diseasesClinical and Translational Medicine, 2022
- Biogenesis and mechanisms of microRNA‐mediated gene regulationBiotechnology and Bioengineering, 2022
- Circular RNA translation, a path to hidden proteomeWIREs RNA, 2021
- Promoter hypermethylation of the CFTR gene as a novel diagnostic and prognostic marker of breast cancerCell Biology International, 2019
- RNA therapeutics: Identification of novel targets leading to drug discoveryJournal of Cellular Biochemistry, 2019
- Long noncoding RNAs: Novel regulators of virus‐host interactionsReviews in Medical Virology, 2019
- The circRNA–microRNA code: emerging implications for cancer diagnosis and treatmentMolecular Oncology, 2019